AR and neoplasm: Previous work has shown that beta‐blockers can inhibit the pro‐tumor effects of β1 and β2‐AR, such as proliferation, migration, angiogenesis, resistance to anoikis, as well as downregulate the expression of pro‐tumor molecules such as angiogenic factors and interleukins.6, 20, 21, 22, 23, 24, 25